Search

Author/Creator Rediti, Mattia

1. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. (1st January 2020)

Authors:
Incorvaia, Lorena; Fanale, Daniele; Badalamenti, Giuseppe; Porta, Camillo; Olive, Daniel; De Luca, Ida; Brando, Chiara; Rizzo, Mimma; Messina, Carlo; Rediti, Mattia; Russo, Antonio; Bazan, Viviana; Iovanna, Juan Lucio
Journal:
Oncoimmunology
Issue:
Volume 9:Number 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients. (1st November 2012)

Authors:
Neri, Bruno; Vannini, Agnese; Brugia, Marco; Muto, Andrea; Rangan, Sheila; Rediti, Mattia; Tassi, Renato; Cerullo, Carmine
Journal:
International journal of urology
Issue:
Volume 20:Number 5(2013)
Page Start:
478
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search